Intensity Therapeutics Inc (INTS) - Debt to Equity

The price visualization on GURU.Markets for Intensity Therapeutics (INTS), which assists in the basic valuation of the asset, demonstrates a metric at 0.01. Intensity Therapeutics optimizes the search for anti-tumor compounds by utilizing AI and robotics to eliminate routine operations. The direct delivery of drugs into neoplasms without systemic toxicity provides the company with significant pricing power. Patent protection for the intratumoral method creates a serious advantage over traditional treatment modalities.

When constructing a long-term portfolio, fundamental screening requires an assessment of financial stability through the balance of debt and equity. This metric measures the proportion of liabilities within the capital structure, which is critical for Intensity Therapeutics (INTS) as it scales the INT230-6 platform and captures the immunotherapy market, as the debt-to-equity ratio determines the company's margin of safety during costly clinical trials.